Skip to main content
. 2021 Feb 12;16:11. doi: 10.1186/s13722-021-00220-2

Table 3.

Timeline of assessments

Assessments Screening Randomization Baselined Day 1d Day 2 Day 3 Day 4 Day 7

Experimental arm: rapid micro-induction

(E stands for experimental arm assessments)

 graphic file with name 13722_2021_220_Figa_HTML.gif

Control arm: standard induction

(C stands for control arm assessments)

 graphic file with name 13722_2021_220_Figb_HTML.gif
Informed consent form

E

C
Physical examination

E

C

E

C

E

C

E

C

E

C

 E
Medical history

E

C
Pregnancy test

E

C
Blood testsa

E

C
Viral profileb

E

C
Urine drug screens

E

C

E

C

 C E
Opiate treatment index (OTI)—health section

E

C
Treatment outcomes profile (TOP)

E

C

 C E
Clinical Opiate Withdrawal Scale (COWS)

Ec

Cc

Ec

Cc

 Ec
Numeric Rating Scale for craving

Ec

Cc

Ec

Cc

 Ec
Numeric Rating Scale for pain

Ec

Cc

Ec

Cc

 Ec
Treatment Perceptions Questionnaire (TPQ) C E
Assessment of treatment retention

E

C
Adverse event report form

E

C

E

C

E

C

E

C

 E

aComplete blood count (CBC), Extended lytes, Liver function

bHepC serology, HepB antigen, HIV Elisa

cThe COWS and Numeric Rating Scales for craving and pain will be administered at baseline, every 1.5 h during the abstinence period (control arm only), and throughout the induction process for both arms (days 1 to 2 of the experimental arm, and day 1 of the control arm)—specifically, immediately before each dose of buprenorphine/naloxone, and 1 to 1.5 h after each dose of buprenorphine/naloxone

dBaseline and day 1 assessments may be done on the same day, depending on the time of day the participants are recruited in the study and the state they are in when they are recruited